Browsing by Author "Diamond, Joana"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Genetic variants of ABC and SLC transporter genes and chronic myeloid leukaemia: impact on susceptibility and prognosisPublication . Alves, Raquel; Goncalves, Ana Cristina; Jorge, Joana; Marques, Gilberto; Ribeiro, André B.; Tenreiro, Rita; Coucelo, Margarida; Diamond, Joana; Oliveiros, Bárbara; Pereira, Amélia; Freitas-Tavares, Paulo; Almeida, António M.; Sarmento-Ribeiro, Ana BelaSolute carrier (SLC) and ATP-binding cassette (ABC) transporters comprise a variety of proteins expressed on cell membranes responsible for intrusion or extrusion of substrates, respectively, including nutrients, xenobiotics, and chemotherapeutic agents. These transporters mediate the cellular disposition of tyrosine kinase inhibitors (TKIs), and their genetic variants could affect its function, potentially predisposing patients to chronic myeloid leukaemia (CML) and modulating treatment response. We explored the impact of genetic variability (single nucleotide variants—SNVs) of drug transporter genes (ABCB1, ABCG2, SLC22A1, and SLC22A5) on CML susceptibility, drug response, and BCR-ABL1 mutation status. We genotyped 10 SNVs by tetra-primers-AMRS-PCR in 198 CML patients and 404 controls, and assessed their role in CML susceptibility and prognosis. We identified five SNVs associated with CML predisposition, with some variants increasing disease risk, including TT genotype ABCB1 (rs1045642), and others showing a protective effect (GG genotype SLC22A5 rs274558). We also observed different haplotypes and genotypic profiles associated with CML predisposition. Relating to drug response impact, we found that CML patients with the CC genotype (rs2231142 ABCG2) had an increased risk of TKI resistance (six-fold). Additionally, CML patients carrying the CG genotype (rs683369 SLC22A1) presented a 4.54-fold higher risk of BCR-ABL1 mutations. Our results suggest that drug transporters’ SNVs might be involved in CML susceptibility and TKI response, and predict the risk of BCR-ABL1 mutations, highlighting the impact that SNVs could have in therapeutic selection.
- Influence of genetic variants of oxidative stress related genes on prognosis and therapy response in chronic myeloid leukemiaPublication . Alves, Raquel; Ventura, Filipa; Jorge, Joana; Ribeiro, Ilda P.; Marques, Gilberto; Coucelo, Margarida; Diamond, Joana; Freitas-Tavares, Paulo; Almeida, António; Goncalves, Ana Cristina; Sarmento-Ribeiro, Ana BelaChronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of BCR-ABL1 oncogene. Oxidative stress conditions are crucial in tumor development and progression. The NRF2, codified by NFE2L2 gene, plays a central role in redox balance, promoting the transcription of cytoprotective and antioxidant genes such as SOD2, GPX1 and CAT. The action of this transcription factor is regulated by KEAP1. Alterations in these genes, either due to somatic mutations or genetic variants (SNV), have been associated with the development, prognosis, and therapeutic response in cancer. This work evaluated the influence of polymorphisms in genes associated with oxidative stress (NFE2L2, KEAP1, SOD2, GPX1, and CAT) in prognosis and treatment response with tyrosine kinase inhibitors (TKI) in CML patients. In 194 CML samples, nine genetic variants in NFE2L2 (rs6721961, rs4893819, rs35652124, rs6706649 and rs13001694), KEAP1 (rs113540846), SOD2 (rs4880), GPX1 (rs1050450) and CAT (rs1001179) were genotyped by PCR based assays. The association of these genetic variants with clinical-laboratory characteristics were assessed by Fisher’s test, logistic regression, and Kaplan-Meier curves, considering a p<0.05. The results obtained showed that patients with G allele on GPX1 rs1050450 and KEAP1 rs113540846 variants have an approximately 2-fold and 31-fold higher probability of being TKI resistant, respectively. In TKI-resistant group, patients with CT genotype in NFE2L2 rs4893819 variant were more likely to need three or more lines of treatment (OR=5.60, 95%CI 1.22-25.75, p=0.027). An important factor for TKI response is BCR-ABL1 mutational status, and we found that individuals with AG genotype in NFE2L2 rs13001694 present, approximately 9x more risk of mutation on this fusion gene. Moreover, patients heterozygous for the NFE2L2 rs4893819 (CT genotype) and SOD2 rs4880 (AG genotype) variants have faster disease progression [NFE2L2: hazard ratio (HR)=7.84, 95% CI 1.82-29.93, p=0.020; SOD2: HR=7.19, 95% CI 1.62-31.96, p=0.035] comparing with other genotypes. While the GG genotype of the NFE2L2 rs13001694 variant has a 2-fold lower overall survival than other patients (HR=11.86, 95% CI 1.39-1000.7, p=0.023). Additionally, we also observed an association between haplotypes and genotypic profile with CML prognosis. In conclusion, our results suggest that genetic variants in genes associated with the redox state might be important factors in the prognosis, survival, and therapy response in CML patients.